Zhang Yuhang, Zhang Chunyuan
Department of Stomatology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Department of Stomatology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
J Indian Soc Periodontol. 2023 Jul-Aug;27(4):428-433. doi: 10.4103/jisp.jisp_229_22. Epub 2023 Jul 1.
To evaluate the clinical efficacy of Crestal Sinus Augmentation (CSA) in a head back position (CSA-HBP) for maxillary sinus mucosa elevation.
We enrolled 209 patients, 246 maxillary sinuses, 348 sites in this study. Complications, maxillary sinus mucosal perforation rate and cumulative survival rate (CSR) data were collected to evaluate the clinical efficacy of CSA-HBP. Maxillary sinus mucosal elevation height (EH) and new bone height (NH) were measured by cone-beam computerized tomography and standard periapical radiographs. The implantation sites of residual bone height (RBH) ≤5 mm and RBH >5 mm were marked as Groups A ( = 81) and B ( = 267), respectively. The implantation sites of the second and third molar sites were marked as Group C ( = 134), and the remaining sites were marked as Group D ( = 214).
The RBH before implant placement was 6.63 ± 2.10 mm (95% confidence interval [CI] 6.41- 6.85 mm). The mucosal EH was 4.04 ± 1.86 mm (95% CI 3.85 - 4.24 mm). The NH was 2.36 ± 1.20 mm (95% CI 3.85-4.24 mm). No other complications were found except three cases of postoperative swelling and one case of nasal blood secretions. The overall mucosal perforation rate was 1.44% (5/348, 95% CI 0.2%-2.7%) and the rate of RBH ≤ 5 mm (Group A) was 1.49% (2/134, 95% CI 0%-3.50%). The 8-year CSR was 99.71% (347/348, 95% CI 99.2%-100.0%). Mucosal EH and NH were higher in RBH ≤5 mm (Group A) than in RBH >5 mm (Group B) ( = 0.001 and = 0.001, Mann-Whitney -test). There were no significant differences in mucosal EH and perforation rate between second and third molar sites (Group C) and other sites (Group D) ( = 0.77, Mann-Whitney -test, and = 0.16, Yates' Chi-square independence test).
CSA-HBP is a minimally invasive and reliable technique.
评估头后仰位嵴顶窦底提升术（CSA-HBP）在上颌窦黏膜提升中的临床疗效。
本研究纳入209例患者、246个上颌窦、348个位点。收集并发症、上颌窦黏膜穿孔率和累积生存率（CSR）数据以评估CSA-HBP的临床疗效。通过锥形束计算机断层扫描和标准根尖片测量上颌窦黏膜提升高度（EH）和新骨高度（NH）。残余骨高度（RBH）≤5mm和RBH>5mm的种植位点分别标记为A组（n = 81）和B组（n = 267）。第二和第三磨牙位点的种植位点标记为C组（n = 134），其余位点标记为D组（n = 214）。
种植前RBH为6.63±2.10mm（95%置信区间[CI]6.41 - 6.85mm）。黏膜EH为4.04±1.86mm（95%CI 3.85 - 4.24mm）。NH为2.36±1.20mm（95%CI 3.85 - 4.24mm）。除3例术后肿胀和1例鼻分泌物带血外，未发现其他并发症。总体黏膜穿孔率为1.44%（5/348，95%CI 0.2% - 2.7%），RBH≤5mm（A组）的穿孔率为1.49%（2/134，95%CI 0% - 3.50%）。8年CSR为99.71%（347/348，95%CI 99.2% - 100.0%）。RBH≤5mm（A组）的黏膜EH和NH高于RBH>5mm（B组）（P = 0.001和P = 0.001，Mann-Whitney U检验）。第二和第三磨牙位点（C组）与其他位点（D组）之间的黏膜EH和穿孔率无显著差异（P = 0.77，Mann-Whitney U检验，P = 0.16，Yates卡方独立性检验）。
CSA-HBP是一种微创且可靠的技术。
